ImageneBio Stock: Why Analysts See 150% Upside Despite Competitor Setbacks
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
Leerink rates ImageneBio stock Outperform with $30 target, calling it "undervalued."
The Trump administration is working on "TrumpRx," a new site connecting consumers to drugmakers, pharmacies, and discount programs like GoodRx to help lower prescription costs.
Pfizer becomes the first pharmaceutical company to announce a drug-pricing deal with the Trump administration, promising lower prices for up to 100 million patients and committing $70 billion to domestic R&D and manufacturing.